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Abstract
Background: Employer-sponsored health risk assessments (HRA) may include laboratory tests to provide evidence of
disease and disease risks for common medical conditions. We evaluated the ability of HRA-laboratory testing to provide new
disease-risk information to participants.
Methodology/Principal Findings: We performed a cross-sectional analysis of HRA-laboratory results for participating adult
employees and their eligible spouses or their domestic partners, focusing on three common health conditions:
hyperlipidemia, diabetes mellitus, and chronic kidney disease. HRA with laboratory results of 52,270 first-time participants
were analyzed. Nearly all participants had access to health insurance coverage. Twenty-four percent (12,392) self-reported
one or more of these medical conditions: 21.1% (11,017) self-identified as having hyperlipidemia, 4.7% (2,479) self-identified
as having diabetes, and 0.7% (352) self-identified as having chronic kidney disease. Overall, 36% (n=18,540) of participants
had laboratory evidence of at least one medical condition newly identified: 30.7% (16,032) had laboratory evidence of
hyperlipidemia identified, 1.9% (984) had laboratory evidence of diabetes identified, and 5.5% (2,866) had laboratory
evidence of chronic kidney disease identified. Of all participants with evidence of hyperlipidemia 59% (16,030 of 27,047),
were newly identified through the HRA. Among those with evidence of diabetes 28% (984 of 3,463) were newly identified.
The highest rate of newly identified disease risk was for chronic kidney disease: 89% (2,866 of 3,218) of participants with
evidence of this condition had not self-reported it. Men (39%) were more likely than women (33%) to have at least one
newly identified condition (p,0.0001). Among men, lower levels of educational achievement were associated with
modestly higher rates of newly identified disease risk (p,0.0001); the association with educational achievement among
women was unclear. Even among the youngest age range (20 to 29 year olds), nearly 1 in 4 participants (24%) had a newly
identified risk for disease.
Conclusions/Significance: These results support the important role of employer-sponsored laboratory testing as an integral
element of HRA for identifying evidence of previously undiagnosed common medical conditions in individuals of all
working age ranges, regardless of educational level and gender.
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Introduction
Employer-sponsored health risk assessments (HRA), a corner-
stone of wellness programs, are used to engage adults in taking
responsibility for their own health, provide feedback that will lead
to behavioral modifications that reduce disease risks, raise
productivity [1,2], and control healthcare expenses [3]. Simply
participating in HRA appears to have benefit [4,5]. HRA are now
being offered by more than 75% of mid- to large-sized companies
[6].
HRA involve a health and lifestyle questionnaire and may
include biometric data (such as weight, body mass index (BMI),
waist circumference, and blood pressure) and laboratory test
results. The inclusion and selection of laboratory tests vary by
program. Self-reported results, even for widely known disease risk
factors such as total cholesterol, are often inaccurate [7]. When
measured laboratory tests are included in HRA, they are typically
limited to total cholesterol, lipid panel (total cholesterol, HDL
cholesterol, calculated LDL cholesterol, and triglycerides) and
fasting glucose. It is less typical to include tests for other common
conditions, such as chronic kidney disease.
This study explores the utility of employer-sponsored laboratory
testing in revealing for new participants evidence of three common
medical conditions: hyperlipidemia, diabetes mellitus, and chronic
kidney disease. These medical conditions were selected because of
their high prevalence in the United States population and the
benefit of effective intervention associated with early detection.
Cardiovascular disease is listed on more than half of all death
certificates [8], and diabetes [9] and chronic kidney disease [10]
are each estimated to affect approximately 26 million Americans.
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screening begin at age 40 years for cardiovascular disease [11], 45
years for diabetes [12], and 60 years for chronic kidney disease
[13]. However, these diseases are growing in prevalence, even in
younger adults, and are often not diagnosed in a timely fashion
[14–15,16,17,18]. Early detection and treatment can delay or
arrest disease progression, and may help to avoid co-morbid
complications. The importance of screening for chronic kidney
disease in particular is often overlooked, increasing the likelihood
for associated kidney failure and cardiovascular events [13,19].
The role and value of laboratory tests within employer-
sponsored HRA have not been well investigated. Among these
limited studies, none appears to have evaluated how often
common chronic diseases are newly identified among such
participants. We explore the frequency of results that are
consistent with increased disease risk and compare this with self-
reported information. This study uniquely focuses on the impact of
age, gender, and education level on the new identification of
common health conditions. Additionally, this study is the first to
assess the role of laboratory testing for chronic kidney disease as
part of an employer-sponsored HRA.
Materials and Methods
Study Population
This was a cross-sectional study of 52,270 first-time participants
ages 20 to 64 years using the Quest Diagnostics Blueprint for
WellnessH HRA. The program was sponsored by 15 employers
representing diverse industries between 2003 and 2010 with
participants from across the United States. To isolate the extent to
which laboratory testing provides new and medically relevant
health risk information, the study was limited to first-time
participants. Participants 65 years and older were excluded from
this study because of the relatively small number. The analysis in
this study was found to be exempt by the Western Institutional
Review Board for the protection of human subject research.
Participants included adult employees and their eligible spouses
or their domestic partners. All of the employers offered healthcare
insurance coverage to their eligible employees and covered family
members.
Evidence of Medical Conditions: Laboratory-Based and
Self-reported Awareness
Three common measurements of hyperlipidemia were used:
total cholesterol above 5.15 millimoles per liter (199 milligrams
per deciliter) [11], low density lipoprotein (LDL) cholesterol above
3.35 millimoles per liter (129 milligrams per deciliter), and total
cholesterol to high density lipoprotein (HDL) cholesterol ratio
above 5.0. Hyperlipidemia was identified if one or more of these
criteria were met. A diagnosis of diabetes mellitus can be based on
fasting glucose levels or hemoglobin A1c levels. For this study, an
elevated fasting glucose level (greater than 6.90 millimoles per liter
(125 milligrams per deciliter)) was considered evidence of diabetes.
Kidney function was assessed with the estimated glomerular
filtration rate (eGFR), a calculation based on serum creatinine,
age, gender, and ethnicity (whether one is identified as African
American or non-African American). eGFR values below 60 mL/
min/1.73 m
2 are indicative of chronic kidney disease stages 3 to 5
[13]. When ethnicity was not reported, eGFR was based on the
non-African American calculation. In a small percentage of
participants (estimated to be fewer than 75 out of 3,218
participants with eGFR results below the threshold), this could
overstate the identification of new chronic kidney disease risk. This
estimate is based on taking all eGFR results between 50 and
59 ml/min/1.73 m
2, inclusive, for whom ethnicity was not
identified (n=527) and multiplying by the percent of African-
Americans identified in the study population (14.0%). This
provided an estimate of the number of unidentified African
Americans who if they were so identified may have had a higher
eGFR based on the MDRD Study equation adjustment factor of
1.21 that applies only to African Americans.
As part of the HRA survey, participants were asked to report
whether they had been informed by a physician that they had any
of the medical conditions included in this study. For these
conditions, a comparison of self-reported disease awareness with
laboratory-based criteria provides an indication of new medical
risk information for each participant. Thus, a medical condition
was considered to be newly identified if it was not self-reported but
the relevant laboratory result(s) exceeded the threshold value. For
example, if a participant reported that he or she had not been
diagnosed with diabetes and the fasting glucose results showed
evidence of diabetes (fasting glucose .125 mg/dL), we classified
the participant as having newly identified diabetes. However, it is
important to note that laboratory results comprise only part of the
diagnostic pathway; further medical evaluation is required for
diagnosis. Furthermore, this methodology only provides a
snapshot of health risk and does not include health risks that
may be reflected in longer-term trends. We used the term ‘‘newly
identified’’ because the medical risk is not ‘‘diagnosed’’ until
confirmed usually with testing on a second specimen and after
excluding other causes of the laboratory finding. Also, we suspect
that some participants may have exceeded the defined criteria
earlier but were not informed by their physicians. Thus, we view
the HRA serving to identify rather than diagnose new disease risks.
Statistical Analysis
Table 1 lists the measures used to assess prevalence of disease
risk and the ability of employer-sponsored HRA with laboratory
testing to identify previously unrecognized medical conditions.
Total disease risk prevalence was defined as the proportion of
participants who self-reported medical condition or had identified
disease risk as a result of employer-sponsored laboratory testing.
Unlike other studies that define prevalence on either self-
identification of disease or laboratory testing, this approach
provides a broader definition of disease prevalence. This enables
us to isolate the contribution of employer-sponsored laboratory
testing in the identification of previously unrecognized disease risk.
The rate of newly identified risk was defined as the proportion
of the total risk-identified population who found out about their
health risks from employer-sponsored laboratory testing.
For each disease, risk prevalence and rate of newly identified
risk are explored by age range, gender, and education level. To
provide greater insight, we characterized the distribution of
participants by the number of disease risks identified. The number
of disease risk identifications for any individual participant ranged
from zero to three (one newly identified risk for each of the three
medical conditions analyzed).
Statistical significance is evaluated using Pearson’s chi-squared
test statistic based on two-sample tests of proportion, performed
using R 2.12.2 (prop.test). Statistical significance for p-value
,0.0001 was reported. Gender comparisons were evaluated with
men as the baseline distribution; age comparisons were evaluated
with 50 to 64 year old participants as the baseline distribution; and
the distribution of participants with high school or less education
was used as the baseline for evaluation of educational impact.
Value of New Lab Tests in Health Risk Assessments
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Study Population
Table 2 summarizes the age and gender distributions of the
study population. The average ages of men and women were 43.4
and 41.7 years, respectively. Women comprised 62.5% of the
study population. Relatively more women than men were
represented in the youngest age range (20 to 29 years) and
relatively more men than women were represented in the oldest
age range (50 to 64 years). Compared to the overall United States
population [20], the study population had a relatively larger
proportion of individuals in the 30 to 49-year age range and a
relatively smaller proportion in other age ranges, particularly the
youngest age group.
Participants came from across the United States, with over-
representation relative to the 2009 United States population [21]
in the Mid- and South-Atlantic census regions, and relative under-
representation in the East North Central and East South Central
census regions (state of residence was not reported for 10.2% of
study population participants). The study population was racially
diverse, with a higher percentage of Asians relative to the similarly-
aged adult United States population. Caucasians and Hispanics
were underrepresented relative to the general population (ethnicity
was not reported for 22.9% of participants).
The study population had a higher representation of high
educational achievement than the general population (educational
attainment was not reported for 0.8% of participants). Overall,
50.8% of the study population had a bachelor or graduate degree.
This compares to only 31.4% for the general United States
population aged 25 years or older.
Prevalence of disease by Self-Identification
Twenty-four percent (12,392) who self-reported one or more of
these medical conditions: 21.1% (11,017 self-identified as having
hyperlipidemia, 4.7% (2,479) self-identified as having diabetes,
and 0.7% (352) self-identified as having chronic kidney disease
Table 3). Men were more likely than women to have each of the
three medical conditions. The prevalence for each of the three
medical conditions increased by age range: among the 50 to 64
year old participants, hyperlipidemia was self-identified in 36.3%,
diabetes in 11.8%, and chronic kidney disease in 12.1%. There
was no clear relationship between educational achievement and
self-identification of hyperlipidemia or chronic kidney disease
whereas there was an inverse relationship between educational
achievement and the self-reported rate of diabetes.
Incidence of Newly Identified Disease Risk
More than a third (35.5%) of participants had laboratory
evidence of one or more disease risk identified through HRA-
laboratory testing (Table 4). Of these, 92.9% had laboratory
evidence of one, 7.0% had evidence of two, and 0.1% had
evidence of all three conditions identified. The rate of newly
identified disease risk increased progressively with age, ranging
from 24.4% among 20 to 29 year olds to 41.7% among 50 to 64
year olds. Among men, lower levels of educational achievement
were associated with modestly higher rates of newly identified
disease risk, ranging from 41.8% for men with high school or less
to 37.0% for men with graduate degrees (p-value,0.0001). There
was no clear relationship between educational achievement and
newly identified disease risk among women. Additionally, we
observed no clear trend in the rate of disease risk identification
over the study period.
Hyperlipidemia
Overall, more than half of the participants (51.7%) either self-
reported hyperlipidemia or had laboratory evidence of hyperlipe-
mia newly identified through the HRA (Table 4). The prevalence
of hyperlipidemia risk was significantly higher among men (60.3%)
than women (46.6%) (p-value,0.0001). While age is a significant
risk factor, we found that the risk for hyperlipidemia began at an
early age, affecting 29.2% of the youngest age group and increased
steadily in older groups.
Of participants with self-reported or laboratory evidence of
hyperlipidemia, the majority (59.3%) were newly identified
through the HRA program. The rate of newly identified
laboratory evidence of disease was high for both men (57.5%)
and women (60.6%), and was especially high among the youngest
age range (80.6%). Even among the oldest age group, nearly half
(47.2%) of those with evidence of hyperlipidemia were newly
identified through the HRA. No clear trend was observed between
educational attainment and newly identified risk of hyperlipide-
mia.
Diabetes Mellitus
The total diabetes risk prevalence was 6.6% in our study
population (Table 4). This included participants who self-reported
a medical condition or newly identified their health risk through
the HRA. The diabetes risk prevalence was significantly higher
among men (8.0%) than women (5.8%) (p-value,0.0001). Risk for
diabetes began at an early age, affecting 1.7% of adults aged 20 to
29 and 3.5% of adults aged 30 to 39 years. Among 50 to 64 year
olds, the risk of diabetes was 11.8%. There was an inverse
relationship between advancing educational attainment and
diabetes risk prevalence: diabetes risk was found in 9.2% of adults
with high school education or less and 5.0% of those adults with
graduate degrees.
Among participants with self-reported or laboratory evidence of
diabetes, 28.4% were newly identified through this program.
Newly identified disease risk was slightly higher among men
(30.5%) than women (26.7%) (p-value,0.0001). Nearly 2 in 5
(38.7%) participants with diabetes risk in the youngest age range
(20 to 29) were newly identified; nearly 1 in 4 (23.9%) participants
between 50 and 64 years old were newly identified. No trend was
observed between educational attainment and risk of newly
identified diabetes risk.
Table 1. Measurements Used to Characterize Disease Prevalence and the Rate of Newly Identified Disease Risk.
Metric Description
Total Disease Prevalence Proportion of first time participants who self-reported medical condition or were newly
identified disease risk as a result of employer-sponsored laboratory testing.
Rate of Newly Identified Disease Risk Proportion of the total disease population who found out about their health risks from
employer-sponsored laboratory testing.
doi:10.1371/journal.pone.0028201.t001
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The total chronic kidney disease risk prevalence was 6.2% in
our study population (Table 4). This included participants who
self-reported or newly identified their chronic kidney disease risk
through the HRA. The chronic kidney disease risk prevalence was
slightly lower among men (5.7%) than women (6.4%) (p-
value,0.0001). Risk for chronic kidney disease was identified
beginning at an early age, affecting 1.0% of adults aged 20 to 29
and 2.7% of adults aged 30 to 39 years. Among 50 to 64 year olds,
the risk of chronic kidney disease was 12.1%. As noted in Table 4,
the prevalence of total disease risk was similar for chronic kidney
disease and diabetes.
Among participants with self-reported or laboratory evidence of
chronic kidney disease, 89.1% were newly identified through this
program. The rates of newly identified disease risk were slightly
lower among men (87.0%) than women (90.2%) (p-value,0.0001),
but age had a marked effect on the likelihood of a disease being
newly identified. No trend was observed between educational
attainment and risk of newly identified chronic kidney disease.
Discussion
More than one in three study participants had laboratory
evidence of at least one common medical condition newly
identified. The results of this study support the use of laboratory
testing along with HRA questionnaires to identify previously
unrecognized disease risk in individuals of all working age ranges,
regardless of educational level and gender.
Ideally adults with healthcare insurance would avail them-
selves of medical services that are typically covered by their
health plans, including routine physical examinations and
laboratory tests. Yet, many adults do not seek preventive medical
care in the absence of symptoms [22]. In one poll of men, 36%
indicated they would go to the doctor only if ‘‘extremely sick’’
[23]. HRA with a laboratory component can address this
shortcoming by uncovering disease risk factors and driving
participants to seek medical care when risks are identified.
Recognizing this, many employers increasingly offer HRA with
laboratory tests.
Table 2. Description of Study Population.
Percent of Study Population
(n=52,270)
Percent Among
Men
(n=19,593)
Percent Among
Women
(n=32,677)
Age Range (years)
20–29 15.3 12.5 16.9
30–39 25.5 24.8 26.0
40–49 30.0 30.4 29.8
50–64 29.2 32.3 27.3
Average Age 42.3 years 43.4 years 41.7 years
Education
{
High School (or less) 16.2 17.5 15.4
Some College 33.0 28.9 35.4
Bachelor’s Degree 35.7 36.5 35.3
Graduate Degree 15.1 17.2 13.9
Ethnicity
{
Caucasian 56.0 58.5 54.5
Asian 16.0 17.7 15.0
African American 14.0 9.4 16.7
Hispanic 10.5 11.0 10.2
American Indian 0.4 0.4 0.4
Other 3.1 3.0 3.2
U.S. Region
*
New England 3.7 3.6 3.7
Mid-Atlantic 17.5 17.9 17.2
East North Central 9.1 9.0 9.2
West North Central 7.5 7.7 7.4
South Atlantic 26.9 22.6 29.3
East South Central 2.1 2.3 1.9
West South Central 13.3 16.4 11.6
Mountain 4.7 4.4 4.9
Pacific 15.2 16.1 14.6
{Educational attainment was not reported for 0.8% of participants. ‘‘Some College’’ educational category includes vocational training and associate’s degree.
{Ethnicity was not reported for 22.9% of participants. ‘‘Other’’ ethnicity category includes responses for ‘‘other’’ and ‘‘multi-ethnic’’.
*State of residence was not reported for 10.2% of study population participants.
doi:10.1371/journal.pone.0028201.t002
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The percent of participants with newly identified disease risk
(35.5%) was significantly higher than the percent of participants
who self-identified (23.7%) as having one or more of these three
conditions. This high rate of newly identified risk suggests that our
current healthcare system fails to identify common disease risk
factors for a large number of working-age people, even for those
with access to quality healthcare. Our study also suggests that
without employer-sponsored laboratory testing, more than 1 in 3
working-age adults may have unidentified disease(s). When left
untreated these conditions can progress to more advanced stages
with irreversible harm and needless expense. If we extend this
observation to the United States population aged 20 to 64 years,
67 million Americans have undiagnosed laboratory markers for
hyperlipidemia, diabetes, and/or chronic kidney disease. Our
findings are consistent with broader population studies that
include non-working adults of all ages [15,24,25], and further
accentuate the importance of including laboratory testing in
employer-sponsored HRA.
Importance of Testing for Chronic Kidney Disease
The high prevalence of diabetes (25.8 million in the United
States) is well recognized. Although chronic kidney disease has a
similar prevalence (26.3 million) [26] awareness of this condition is
low even among those affected. In our study, 89.1% of participants
with self-reported or laboratory evidence of chronic kidney disease
were unaware of their condition. This compares to 28.4% for
diabetes and 59.3% for hyperlipidemia. Early detection and
treatment can slow or halt the progression of chronic kidney
disease and associated co-morbidities [27], including cardiovascu-
lar disease and diabetes. The findings of this study complement
other research supporting the inclusion of chronic kidney disease
testing in employer-sponsored HRA [28].
Benefits of Testing Are Widespread
Our study found that the benefits of employer-sponsored
laboratory testing are widespread, with high rates of disease risk
identification for both men and women, and across all age ranges
and educational achievement.
While the rates of disease risk identification were high for all
populations, some groups were impacted more significantly than
others. Men under the age of 50 years had a higher rate of newly
identified risk than women. This may be due, in part, to lower
outpatient physician visit rates among men relative to women [29].
Interestingly, the pattern of newly identified disease risk reverses
among participants 50 to 64 years of age, with women having a
higher rate of newly identified disease risk than men. While the
reason for this reversal is unclear, it is possible that men in their
50 s are increasingly aware and responsive to guidelines suggesting
population screening for a variety of medical conditions, including
general guidelines for colorectal cancer screening and discussion of
prostate cancer screening beginning at age 50 years [30].
Professional guidelines typically recommend testing be initiated
in middle-aged and older adults who are not otherwise at high
disease risk [12,31]. Younger people are less likely to have a
personal physician and to seek preventative medical care. Studies
have shown that younger adults are heavier [32] and more
sedentary than ever, and therefore exhibit many more risk factors
than earlier generations for the three medical conditions included
in this study. Our study suggests that these three conditions are
more common among younger aged adults than is generally
recognized. For participants with evidence of hyperlipidemia or
diabetes, our study found that younger participants were less likely
to be aware of their condition. Even though the rate of newly
identified chronic kidney disease increases with age, more than 3
out of 5 of the youngest participants with chronic kidney disease
were newly identified. Our study demonstrates that employer-
sponsored HRA with laboratory testing reveals important health
risk information even for younger ages. This supports the value of
offering broad-based population screening across all ages.
Many studies from around the world support the relationship
between health literacy and better health outcomes [33–34,35,36].
Although health literacy increases with educational attainment, it
still remains below proficient for two-thirds of graduate degree
recipients [37]. Our study suggests that educational achievement
provides little benefit in the early identification of these three
common diseases.
Study Limitations
Cross-Sectional Population. This study reflects the specific
health awareness and promotion activities performed by 15
employers. Experience of other employers may differ. The study
population differs from the general working-age population in
being more highly educated, over-representing women, and
somewhat skewed based on geography and ethnicity. Contrary
to prevalent beliefs, these factors had no or minimal impact on our
findings suggesting that selection-bias would likewise have had no
or minimal influence on our results. While these differences could
limit the applicability of these results to the broader working-age
population, our findings on disease risk prevalence are broadly
consistent with large population studies [16,24,25].
The specific characteristics of incentive programs offered by the
15 employers may contribute to attracting different participants
with different disease profiles. Further, employees already under
medical care or in the other extreme, healthy employees, may
have chosen not participate. Participants may have participated in
other HRA prior to participation in Quest Diagnostics Blueprint
for Wellness through their current or previous employers.
Accuracy of Self-Reported Disease Awareness. Preexisting
knowledge of hyperlipidemia, diabetes, or chronic kidney disease is
based on self-reported data. Differences in how terminology is
understood may influence reported pre-existing awareness.
Table 4. Percent of Participants with One or More Newly
Identified Disease Risks.
Total Men Women
Study Population 35.5 39.4 33.1
a
Age Range, years
20–29 24.4
b 31.1
b 21.4
a,b
30–39 31.8
b 41.5
b 26.3
a,b
40–49 38.1
b 42.8
b 35.2
a,b
50–64 41.7 37.7 44.6
a
Education
High school or less 37.9 41.8 35.3
a
Some college or vocational training 34.6
c 40.0
c 32.0
a,c
Bachelor’s degree 34.8
c 38.9
c 32.3
a,c
Graduate degree 36.3
c 37.0
c 35.7
a
ap-value,0.0001 for comparison with men.
bp-value,0.0001 for comparison with 50–64 year olds.
cp-value,0.0001 for comparison with high school or less.
doi:10.1371/journal.pone.0028201.t004
Value of New Lab Tests in Health Risk Assessments
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28201Subjective factors regarding self-perception and denial may have
adversely influenced how the respondents self-reported.
Disease Confirmation. Our disease classification is based
on laboratory testing from a single blood collection. Although the
diagnostic thresholds used are consistent with professional
guidelines, a medical diagnosis requires confirmation of test
results and syntheses with other clinical findings. Due to biological
and analytical variation, it is commonly accepted clinical practice
that for these three medical conditions individuals whose
laboratory test results exceed diagnostic criteria be retested.
Thus, the single observations in this study may over-estimate
undiagnosed chronic medical conditions. For example, many
factors influence measurement of fasting glucose [38]. An
NHANES III study examining the reproducibility of fasting
glucose testing in adults newly identified with diabetes showed that
70.4% had confirmation of their results [39]. Although
confirmatory testing is appropriate on an individual basis, our
methodology is consistent with other population-based studies,
such as NHANES and the Framingham Heart Study, that use
laboratory test results from a single snapshot in time.
Future Directions
This study focuses on newly detected disease. Additional
research is needed to assess the role of HRA in disease prevention.
Furthermore, studies that track laboratory results of HRA
participants over time are needed to assess and improve
management of chronic diseases. Finally, the ability of HRA
participation to modify behaviors (such as diet, exercise, smoking,
and use of preventive services) needs to be investigated,
particularly their impact on disease risks measured by laboratory
tests.
Specific topics for future research include: 1) whether
individuals with newly identified disease risk seek medical care;
2) the optimal frequency for employer-sponsored HRA with
laboratory testing; and 3) the appropriate use of personalized
testing based on demographic factors (e.g., age, gender, and/or
education level), family history, and other biometrics such as BMI
and blood pressure.
Summary
In summary, our findings show that, for a large proportion of
working-age adults, healthcare access alone does not guarantee
detection of risk factors for common chronic health conditions.
The availability of HRA with laboratory tests serves an important
role in addressing this shortcoming. By identifying such opportu-
nities early, employer-sponsored laboratory testing may slow or
prevent the progression of common medical conditions. This has
clear benefit to employees and their spouses and their domestic
partners, regardless of age, gender, and educational achievement.
Similarly, employers who bear much of the financial costs of poor
disease management may benefit from early detection and
treatment that can help to avert healthcare costs associated with
advanced disease.
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